$184.15
-1.47 (-0.79%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GKOS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
61 interventional · 5 observational · 13 with posted results
Held by 20 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, MILLENNIUM MANAGEMENT LLC, Holocene Advisors, LP, CITADEL ADVISORS LLC, Balyasny Asset Management L.P., +15 more) · FINRA short interest 3.6 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral ImplantNCT07495852Intraocular pressure (IOP)Randomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5% · Procedure: Sham Procedure · Other: placebo eye drops | Glaucoma | 510 | Jun 2028 | ≤ 681 d | 2026-03-30 |
| Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral ImplantNCT07075718Intraocular pressure (IOP)Randomized · Triple-masked · Treatment | Phase 2/3 | Recruiting | Drug: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5% · Procedure: Sham Procedure · Other: Placebo eye drops | Glaucoma | 610 | Mar 2028 | ≤ 590 d | 2026-03-02 |
| Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for KeratoconusNCT07629557Successful completion of bilateral epithelium-on corneal collagen cross-linking.Open-label · Treatment | Phase 4 | Recruiting | Drug: Riboflavin Ophthalmic Solutions · Device: UV-A Irradiation System | Keratoconus | 15 | Sep 2027 | ≤ 407 d | 2026-06-05 |
| Travoprost Intraocular Implant + iStent InfiniteNCT06066645change from baseline in mean diurnal intraocular pressure (IOP)Randomized · Double-masked · Treatment | Phase 4 | Recruiting | Drug: Travoprost Intraocular Implant · Device: iStent infinite · Other: Sham procedure | Glaucoma, Open-Angle | 150 | May 2027 | ≤ 285 d | 2026-06-02 |
| Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With KeratoconusNCT07400952Mean change from baseline in maximum corneal curvatureRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: GLK-221 Ophthalmic Solution, Placebo Ophthalmic Solution | Keratoconus | 100 | Apr 2027 | ≤ 254 d | 2026-02-10 |
| Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex BlepharitisNCT07400965Percentage of study eyes with elimination of collarettesRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: GLK-321 low dose BID, GLK-321 mid dose BID, GLK-321 high dose BID, GLK-321 high dose QD, Placebo BID | Demodex Blepharitis | 250 | Sep 2026 | ≤ 42 d | 2026-02-27 |
| Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery AloneNCT06848946Change from baseline in mean diurnal IOPRandomized · Double-masked · Treatment | Phase 4 | Recruiting | Combination product: iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery · Procedure: Sham procedure in conjunction with cataract surgery | Glaucoma, Open-angle, Ocular Hypertension (OHT), Phacoemulsification Cataract Surgery | 132 | Aug 2026 | ≤ 12 d | 2026-01-21 |
| Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcgNCT07400926observationalSuccessful implantation | — | Recruiting | Combination product: Travoprost | Open Angle Glaucoma (OAG), Ocular Hypertension (OH) | 30 | Jun 2026 | — | 2026-02-27 |
| A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCEDNCT05966493Achieve Corneal Re-epithelialization Including Durability (CRC)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: lufepirsen high dose, Vehicle, lufepirsen low dose | Persistent Corneal Epithelial Defect | 84 | Dec 2025 | — | 2025-07-24 |
| Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle GlaucomaNCT06057051Mean Diurnal Intraocular Pressure (IOP) 12-Month reduction ≥ 20% from BaselineOpen-label · Treatment | Not applicable | Recruiting | Device: iStent Infinite | Glaucoma | 245 | Aug 2025 | — | 2023-09-28 |
| Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. CompetitorNCT05127551Change in Mean Diurnal Intraocular PressureRandomized · Double-masked · Treatment | Not applicable | Active, not recruiting | Device: iStent Infinite, Competitor Device | Glaucoma, Glaucoma, Open-Angle | 179 | 2024-02-29actual | — | 2024-08-15 |
| iStent Inject New Enrollment Post-Approval StudyNCT04624698iStent inject placement and stabilityOpen-label · Treatment | Not applicable | Unknown status | Device: iStent Inject Implantation | Glaucoma, Open-Angle, Glaucoma | 358 | May 2026 | — | 2024-02-23 |
| Observational Registry to Assess the Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive SurgeryNCT03319082observationalKmax | — | Unknown status | Combination product: Corneal Collagen Cross-linking | Corneal Ectasia | 200 | Feb 2026 | — | 2024-02-23 |
| Safety and Efficacy of Corneal Cross-linking in Subjects With KeratoconusNCT05314738TopographyRandomized · Single-masked · Treatment | Phase 1/2 | Unknown status | Combination product: NXL Energy 1, NXL Energy 2, NXL Energy 3, Sham Treatment | Progressive Keratoconus | 150 | Aug 2025 | — | 2024-07-08 |
| Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular HypertensionNCT06152861change from baseline in mean diurnal IOP in the study eyeRandomized · Quadruple-masked · Treatment | Phase 2 | Unknown status | Drug: Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004% | Open Angle Glaucoma, Ocular Hypertension | 250 | Aug 2024 | — | 2023-12-06 |
| Travoprost Intraocular Implant in Conjunction With Cataract SurgeryNCT06061718Change from baseline in mean diurnal IOPOpen-label · Treatment | Phase 3 | Unknown status | Drug: iDose TR | Open Angle Glaucoma, Ocular Hypertension | 60 | 2024-03-18actual | — | 2024-06-03 |
| Performance of the Travoprost Intraocular ImplantNCT06582732results2024-10-15Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administrationNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Travoprost Intracameral Implant exchanged at Month 12, Travoprost Intracameral Implant exchanged at Month 3, Travoprost Intracameral Implant exchanged at Month 6, Travoprost Intracameral Implant exchanged at Month 24, Travoprost intracameral implant exchanged at Month 21, Travoprost intracameral implant exchanged at Month 18, Travoprost intracameral implant exchanged at Month 15 | Glaucoma, Open-Angle, Ocular Hypertension | 210 | 2023-11-02actual | — | 2024-10-15 |
| Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of PresbyopiaNCT05124275Binocular Distance Corrected Near Visual Acuity (DCNVA)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream | Presbyopia | 123 | 2022-09-06actual | — | 2023-09-01 |
| Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye DiseaseNCT05119920Mean change from baseline in the VAS score at Day 28 visit.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream | Dry Eye Disease, Kerato Conjunctivitis Sicca | 226 | 2022-07-27actual | — | 2023-07-12 |
| Clinical Study Comparing Two Models of a Travoprost Intraocular ImplantNCT03868124results2023-09-26Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months PostoperativeRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Combination product: G2-TR intraocular implant containing travoprost · Drug: Sham surgery + active-comparator eye drops | Glaucoma, Open-Angle, Ocular Hypertension | 560 | 2022-06-10actual | — | 2024-11-29 |
| Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%NCT03519386results2023-09-14Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months PostoperativeRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Combination product: G2-TR intraocular implant containing travoprost · Drug: Sham surgery + active-comparator eye drops | Glaucoma, Open-Angle, Ocular Hypertension | 590 | 2022-04-05actual | — | 2024-11-29 |
| Study of Exchange of Travoprost Intraocular ImplantNCT04615403results2023-09-26Ocular SafetyOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Travoprost | Open Angle Glaucoma | 33 | 2022-02-28actual | — | 2023-09-26 |
| NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular InjuriesNCT04081103results2024-10-23The Proportion of Subjects Achieving Corneal Epithelial Recovery, as Assessed by Slit Lamp Examination.Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was stopped early (n=35) enabling the data to guide design of the subsequent clinical study. | Drug: Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle, Open-label Nexagon® (lufepirsen) | Corneal Persistent Epithelial Defect | 35 | 2022-02-07actual | — | 2025-07-14 |
| Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory GlaucomaNCT03639870Primary effectiveness endpointOpen-label · Treatment | Not applicable | Unknown status | Device: Model iS3 three-stent trabecular micro-bypass system | Glaucoma | 65 | Sep 2021 | — | 2021-04-23 |
| Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract SurgeryNCT01841450Rate of sight-threatening adverse eventsNon-randomized · Open-label · Treatment | Not applicable | Unknown status | Device: iStent · Procedure: Cataract surgery | Primary Open Angle Glaucoma | 360 | Aug 2021actual | — | 2021-10-20 |
| iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval StudyNCT04624685observationaliStent inject Placement and Stability | — | Unknown status | — | Glaucoma, Open-Angle | 475 | 2021-01-20actual | — | 2021-10-20 |
| iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive MedicationsNCT03478293IOP reduction at 12 and 24 months on same number or fewer medicationsOpen-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Business Decision | Device: iStent inject surgery | Primary Open Angle Glaucoma (POAG) | 6 | 2020-12-30actual | — | 2022-09-09 |
| A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal StentNCT01252914Mean diurnal Intraocular Pressure reduction of greater than or equal to 20% at month 12 vs. baselineOpen-label · Treatment | Phase 4 | Completed | Device: iStent Supra Stent | Subject With Primary Open-angle Glaucoma (POAG) | 80 | 2019-12-16actual | — | 2022-09-07 |
| Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One iStent and One iStent SupraNCT0325578520% IOP reduction from baselineOpen-label · Treatment | Not applicable | Completed | Device: Cataract surgery plus one iStent and one iStent Supra implanted | Glaucoma, Open-Angle | 15 | 2019-12-03actual | — | 2022-09-09 |
| Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive MedicationNCT02868190Mean intraocular pressure reduction of 20% or more vs baselineOpen-label · Treatment | Phase 4 | Completed | Device: Two trabecular micro-bypass stents (iStent inject) | Open Angle Glaucoma | 57 | 2019-11-08actual | — | 2022-09-08 |
| Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive AgentsNCT02873806Mean intraocular pressure reduction of 20% or more versus baseline with reduction of 1 medicationOpen-label · Treatment | Phase 4 | Completed | Procedure: Implantation of two iStent inject micro-bypass stents · Drug: Topical travoprost, Tobramycin, Dexamethasone · Device: Two iStent inject micro-bypass stents | Open-angle Glaucoma | 53 | 2019-11-08actual | — | 2022-09-07 |
| Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive KeratoconusNCT03442751results2024-01-30Difference Between Treatment Groups in the Change From Baseline to Month 6 in KmaxRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Test Article A, Test Article B, Placebo · Device: KXL medical device system, KXL medical device system | Progressive Keratoconus | 201 | 2019-11-01actual | — | 2024-01-30 |
| Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract SurgeryNCT01455467Mean diurnal IOP reduction of ≥ 20% vs. baseline mean diurnal IOPRandomized · Single-masked · Treatment | Not applicable | Completed | Device: One iStent, Two iStent | Open-angle Glaucoma | 79 | 2019-10-18actual | — | 2022-08-31 |
| One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma SubjectsNCT01517477Mean diurnal intraocular pressure (IOP) reduction of greater than or equal to 20% at month 12 vs. baselineRandomized · Single-masked · Treatment | Not applicable | Completed | Device: iStent, iStent, iStent | Primary Open Angle Glaucoma (POAG) | 119 | 2019-10-18actual | — | 2022-08-31 |
| Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma SubjectsNCT01252849Mean diurnal IOP reduction of greater than or equal to 20% at month 12 vs. baselineRandomized · Single-masked · Treatment | Not applicable | Completed | Device: iStent, iStent, iStent | Primary Open Angle Glaucoma (POAG) | 119 | 2019-10-08actual | — | 2022-08-31 |
| A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iStent SupraNCT0325579820% IOP reductionOpen-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Business decision | Device: G2 and G3 | Glaucoma, Open-Angle | 7 | 2019-06-06actual | — | 2022-09-09 |
| Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser TrabeculoplastyNCT02327312IOP reductionRandomized · Open-label · Treatment | Not applicable | Terminated | Device: Stents, Laser Trabeculoplasty · Procedure: Laser | Primary Open-Angle Glaucoma | 91 | 2019-05-31actual | — | 2022-12-22 |
| Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser TrabeculoplastyNCT01444105Change from baseline in mean diurnal IOP (mm Hg) at the Month 12 visit.Randomized · Open-label · Treatment | Not applicable | Completed | Device: iStent · Other: SLT | Open-angle Glaucoma | 80 | 2019-04-09actual | — | 2022-08-31 |
| Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or TravoprostNCT01444040Change from screening in mean diurnal IOP (mm Hg) at the Month 12 visit.Randomized · Open-label · Treatment | Phase 4 | Completed | Device: iStent inject · Drug: Travoprost | Open-angle Glaucoma | 196 | 2019-03-28actual | — | 2022-09-08 |
| Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass StentsNCT01456390Subjects observed at Month 12 who experience a mean medicated diurnal IOP reduction of ≥ 20% vs. baseline mean diurnal IOPNon-randomized · Open-label · Treatment | Not applicable | Completed | Device: iStent and iStent supra | Open-Angle Glaucoma | 79 | 2019-03-26actual | — | 2022-09-07 |
| Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract SurgeryNCT01461278≥ 20% Reduction in Intraocular Pressure (IOP)Randomized · Single-masked · Treatment | Not applicable | Completed | Device: iStent supra · Procedure: Cataract surgery | Primary Open-angle Glaucoma | 505 | 2019-03-13actual | — | 2022-05-19 |
| Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract SurgeryNCT01461291≥ 20% Reduction in Intraocular Pressure (IOP)Randomized · Single-masked · Treatment | Not applicable | Completed | Device: iStent inject · Procedure: Cataract surgery | Primary Open-angle Glaucoma | 505 | 2017-08-04actual | — | 2022-05-19 |
| Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic SolutionNCT02754596results2023-08-09IOP (mmHg) Change From Baseline at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Travoprost Intraocular Implant, high elution, Travoprost Intraocular Implant, low elution, Timolol Maleate Ophthalmic Solution, 0.5% | Glaucoma Open-angle | 154 | 2017-08-01actual | — | 2023-09-26 |
| Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or TravoprostNCT01443988Change from screening in mean diurnal IOP (mm Hg) at the Month 12 visit.Randomized · Open-label · Treatment | Phase 4 | Completed | Device: iStent · Drug: Travoprost | Open-angle Glaucoma | 101 | Jan 2017actual | — | 2017-12-18 |
| Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStentsNCT01252862Mean diurnal IOP reduction of greater than or equal to 20% at month 12 vs baselineOpen-label · Treatment | Phase 4 | Completed | Device: iStent | Subjects With Primary Open-angle Glaucoma (POAG) | 40 | Jul 2016actual | — | 2017-12-18 |
| Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStentsNCT01252888mean diurnal IOP reduction of greater than or equal to 20% at Month 12 vs baselineOpen-label · Treatment | Phase 4 | Completed | Device: iStents | Subjects With Primary Open-angle Glaucoma (POAG) | 39 | Jul 2016actual | — | 2022-09-07 |
| Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With KeratoconusNCT01972854Change in Kmax from baselineRandomized · Single-masked · Treatment | Phase 3 | Terminated | Drug: riboflavin solution, placebo solution · Device: KXL System | Keratoconus | 92 | Mar 2016actual | — | 2021-04-26 |
| Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket RegistryNCT01841437observationalRate of sight-threatening adverse events | — | Completed | Device: iStent | Primary Open-angle Glaucoma | 191 | 2016-02-16actual | — | 2017-12-18 |
| Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With KeratoconusNCT01643226Mean change in maximum corneal curvature (Kmax) between the VibeX active treatment group and placebo control groupRandomized · Single-masked · Treatment | Phase 3 | Completed | Drug: riboflavin solution, placebo solution · Device: KXL System | Keratoconus | 230 | Jul 2015actual | — | 2021-04-26 |
| Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With KeratoconusNCT01344187Mean change in maximum corneal curvature (Kmax) between the VibeX active treatment group and placebo control groupRandomized · Single-masked · Treatment | Phase 3 | Completed | Drug: riboflavin solution, placebo solution · Device: KXL System | Keratoconus | 236 | Jun 2015actual | — | 2021-04-26 |
| Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic AstigmatismNCT01893359results2016-10-24MRSE RegressionRandomized · Single-masked · Treatment | Phase 1/2 | Terminated | Drug: riboflavin ophthalmic solution, 0% dextran · Device: UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA), UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off) · Procedure: Laser-assisted in situ keratomileusis | Hyperopia, Hyperopic Astigmatism | 2 | Feb 2015actual | — | 2021-04-26 |
| Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket CohortNCT01836042results2016-04-15observationalRate of Sight-threatening Adverse Events | — | Completed | — | Primary Open Angle Glaucoma | 108 | Apr 2014actual | — | 2016-04-15 |
| GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle GlaucomaNCT01052558Proportion of subjects with 12 month diurnalIOP </= 21 mmHg without use of ocular hypotensive medications for >/= 4 weeks prior to 12 month visit.Randomized · Open-label · Treatment | Phase 3 | Completed | Device: iStent Inject (GTS400) · Procedure: Cataract Surgery | Glaucoma | 164 | Dec 2013actual | — | 2015-05-19 |
| A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle GlaucomaNCT00911924IOP 18 mm Hg or less without medicationsOpen-label · Treatment | Phase 4 | Completed | Device: iStent | Glaucoma, Eye Diseases, Glaucoma, Open-Angle | 112 | Sep 2013actual | — | 2015-05-20 |
| A Study of the iStent in Combo With Cataract Surgery in Newly Diagnosed Open Angle Glaucoma or OH Patients.NCT00326066EfficacyRandomized · Open-label · Treatment | Not applicable | Completed | Device: Glaucoma Surgery · Procedure: cataract surgery only | Open-Angle Glaucoma | 47 | May 2013actual | — | 2018-03-09 |
| A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2NCT00326079EfficacyRandomized · Open-label · Treatment | Phase 4 | Unknown status | Device: Stent | Open-Angle Glaucoma | 61 | May 2013 | — | 2013-03-29 |
| Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)NCT00913029Mean intraocular pressure (IOP)Randomized · Open-label · Treatment | Phase 4 | Completed | Device: iStent · Drug: latanoprost/timolol | Eye Diseases, Glaucoma, Open-Angle, Glaucoma | 192 | Sep 2012actual | — | 2015-05-20 |
| Safety and Efficacy of the GTS400 Stent in Conjunction With CataractNCT00721968results2014-03-06Month 12 Intraocular Pressure ≤ 18 mmHg Without Topical Hypotensive MedicationsRandomized · Open-label · Treatment | Phase 3 | Completed | Device: Glaucoma Stent Surgery (GTS400 Stent) · Procedure: cataract surgery alone | Open-angle Glaucoma | 62 | Feb 2012actual | — | 2014-03-06 |
| Corneal Collagen Cross-Linking for Ectasia (CXL)NCT00674661results2017-01-27Mean Change From Baseline in Maximum Keratometry (Kmax)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: riboflavin ophthalmic solution · Device: UVA Irradiation | Ectasia | 130 | Nov 2011actual | — | 2021-04-26 |
| Clinical Evaluation of the Vedera KXS for the Treatment of Spherical MyopiaNCT00925041UCVA 20/40 or betterOpen-label · Treatment | Not applicable | Completed | Device: Vedera KXS | Myopia | 40 | Aug 2011actual | — | 2021-04-26 |
| Corneal Collagen Cross-linking for Progressive KeratoconusNCT00647699results2016-07-07Mean Change From Baseline in Maximum Keratometry (Kmax)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: riboflavin ophthalmic solution · Device: UVA Irradiation | Progressive Keratoconus | 147 | Apr 2011actual | — | 2021-04-26 |
| Feasibility Study of the Vedera KXS for Treatment of KeratoconusNCT01069848The reduction in Kmax (by keratometry) of >1 DOpen-label · Treatment | Not applicable | Completed | Device: Vedera KXS | Keratoconus | 23 | Mar 2011actual | — | 2021-04-26 |
| A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle GlaucomaNCT00323284results2012-10-04Intraocular Pressure (Measured in mm Hg) Less or Equal to 21 mm Hg on no Topical Hypotensive MedsRandomized · Single-masked · Treatment | Phase 3 | Completed | Device: iStent plus Cataract Surgery · Procedure: Cataract surgery only | Open-Angle Glaucoma | 240 | Jul 2009actual | — | 2018-01-12 |
| A Study of the Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.NCT00326014EfficacyOpen-label · Treatment | Phase 4 | Completed | Device: iStent | Open-Angle Glaucoma | 58 | Mar 2008actual | — | 2015-06-08 |
| A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma SubjectsNCT00326040EfficacyNon-randomized · Open-label · Treatment | Phase 4 | Completed | Device: Glaucoma Surgery | Open-Angle Glaucoma | 45 | — | — | 2008-07-25 |
| Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive SurgeryNCT01643252Mean change in maximum corneal curvature (Kmax) between the VibeX active treatment group and placebo control groupRandomized · Single-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: This study was withdrawn for business reasons. | Drug: riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system, placebo: 0.0% riboflavin ophthalmic solution with the KXL system | Corneal Ectasia | 0 | — | — | 2021-04-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19